Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerChristopher J. Sweeney, Robert S. DiPaola, Maha Hussain et al.|New England Journal of Medicine|2015Cited by 2.8k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyArjun Vasant Balar, Joaquim Bellmunt, Daniel Castellano et al.|The Lancet Oncology|2017Cited by 1.3k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos E. Kyriakopoulos, Christopher J. Sweeney, Yu‐Hui Chen et al.|Journal of Clinical Oncology|2018Cited by 1.1k
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial CarcinomaThomas Powles, Noah M. Hahn, Peter H. O’Donnell et al.|JAMA Oncology|2017Cited by 846
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based ChemotherapyMatthew D. Galsky, Joaquim Bellmunt, Noah M. Hahn et al.|Journal of Clinical Oncology|2011Cited by 686